Compare AMP & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMP | TEVA |
|---|---|---|
| Founded | 1894 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3B | 40.5B |
| IPO Year | 2009 | 1996 |
| Metric | AMP | TEVA |
|---|---|---|
| Price | $553.32 | $38.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $544.91 | $38.63 |
| AVG Volume (30 Days) | 363.0K | ★ 4.1M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | 9.77 | ★ 183.45 |
| EPS | ★ 21.64 | N/A |
| Revenue | ★ $18,911,000,000.00 | N/A |
| Revenue This Year | $1.79 | N/A |
| Revenue Next Year | $4.20 | $2.97 |
| P/E Ratio | $25.77 | ★ N/A |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $422.37 | $18.21 |
| 52 Week High | $572.56 | $38.37 |
| Indicator | AMP | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 57.51 |
| Support Level | $543.97 | $30.42 |
| Resistance Level | $569.95 | $38.37 |
| Average True Range (ATR) | 10.48 | 1.04 |
| MACD | -1.50 | -0.12 |
| Stochastic Oscillator | 63.83 | 64.75 |
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.